OBJECTIVES: Estonia is now considering adding a pneumococcal conjugate vaccine (PCV) in its national immunization program to help reduce the burden of invasive pneumococcal diseases (IPD), pneumonia and acute otitis media (AOM). In this cost-effectiveness analysis (CEA), we estimate the vaccine price under which vaccinating with the pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) is considered cost-effective compared to no vaccination. METHODS: A static cohort model (Knerer et al.